Back to today’s briefing

Story perspectives

Jazz Pharmaceuticals' Modeyso Wins FDA Approval for Brain Tumor Treatment

8/7/2025

29 3

Summary

Story summary

Jazz Pharmaceuticals' Modeyso, a groundbreaking treatment for the aggressive H3 K27M-mutant diffuse midline glioma, has won FDA approval. With a promising 22% response rate from 50 patients, this milestone brings hope to families facing this devastating brain tumor, marking a pivotal moment in the fight against a historically tough disease.

1 of 1

Story summary

Jazz Pharmaceuticals' Modeyso, a groundbreaking treatment for the aggressive H3 K27M-mutant diffuse midline glioma, has won FDA approval. With a promising 22% response rate from 50 patients, this milestone brings hope to families facing this devastating brain tumor, marking a pivotal moment in the fight against a historically tough disease.